KR20020018205A - Injection for impotency - Google Patents

Abstract

PURPOSE: Provided is injection for impotency which contains phentolamine, verapamil and prostagladin E1 and is injected directly into the penis, thereby relieving pains possibly occurred after injection, increasing tetanus of the erect penis and causing no side effect even using it for a long time. CONSTITUTION: The injection for impotency is prepared by mixing 0.05-1.50% of prostagladin E1 which is a vasodilator, 20.00-40.00% of phentolamine and 60.00-80.00% of verapamil in a weight ratio, and adding 0-20% of distilled water for injection thereto.

Description

Erection triggers {INJECTION FOR IMPOTENCY}

The present invention relates to an erectile trigger used in an erectile dysfunction patient whose penis is not properly erected, and more particularly, directly administered to the outside of the penis to effectively erect the penis, reducing pain and increasing stiffness of the erection. It relates to an erectile propellant that can increase the shelf life.

In general, when an erection is a sexual urge, blood is filled from an artery in a sponge-like corpus cavernosum, and the intracavernosal pressure is increased due to the relaxation of the smooth muscle and the compression of the vein.

And men's erectile dysfunction is due to when the blood supply is insufficient or insufficient, when the supply is not blocked by the vein even when supplied, when the intracavernosal pressure is not elevated or is insufficient or maintained for a certain time. If the penis of the human body does not have an erection, even if the erection is not enough to have sex, and the duration of the erection is very short in the erection state, the extent of erectile dysfunction is penile stiffness This can range from a partial reduction in severity to complete erection failure due to sustained impotence.

Of course, for patients with erectile dysfunction, there is a vacuum compressor, angioplasty, penile prosthesis, sexual psychotherapy, hormone therapy, and vasodilator.

Here, the method of administering the vasodilator into the corpus cavernosum causes a rapid erection in a large number of patients and is used as a very successful method. Examples of the method of administering the vasodilator include psychological anxiety, discomfort, and external air caused by pain. Side effects such as infection by bacteria, fibrosis of the penis, hypotension and sustained erection may occur, but a method of directly injecting into the corpus cavernosum is used.

Thus, conventionally, vasodilators used in the penis are used as prostagladin E ₁ (PROSTAGLARDIN E ₁ ), which is directly administered to the corpus cavernosum of erectile dysfunction patients to erect the patient's penis and maintain an erection state for a certain time. Let's do it.

However, the prior art has the disadvantage that the said prostaglandin E the patients treated with ₁ appeal and "prostaglandin E ₁ and a pain occurs during the reaction with blood after the administration.

In addition, since the prostagladin E _{1 in} powder form is mixed with the aqueous solution and used by the patient, there is a further disadvantage that the shelf life is short after the aqueous solution is formed.

In particular, the range of patients capable of erection with prostagladin E ₁ ranges from patients within 50% of erection to inability to maintain a continuous erection, and is not applicable to other patients. .

The present invention has been made to solve the above problems of the prior art, an object of the present invention by adding another agent to the known prostagladin E ₁ directly administered to the penis, pain that may occur after administration It is to provide an stimulant that can reduce the amount of, reduce the erection of the penis effectively, and increase the shelf life.

Therefore, in order to achieve the above object, the present invention provides a known erectile agent comprising prostagladin E ₁ as a vasodilator, wherein the prostagladin E _{1 is} 0.05% to 1.50% and pentolamine 20.00% to 40.00. % And 60.00%-80.00% of verapamil are provided by the weight ratio.

Hereinafter, the erection-producing agent according to the present invention will be described in detail.

Erection inducer according to the present invention is the phosphorus of the vasodilator of the penis known prostaglandin E ₁ (PROSTAGLARDIN E _1), vasodilators President and anti-hypertensive agent is phentolamine amine (PHENTOLAMIN), and vasodilators President and anti-hypertensive agent verapamil (VERAPAMILE) It consists of a mixture.

Namely, in the present invention, 0.05% to 1.5% of the prostagladin E ₁ , 20.00% to 40% of phentolamine, and 60.00% to 80.00% of verapamil are mixed in a weight ratio, and additionally 0% to 20% by weight Distilled water may be used, which is for easy dilution of the mixture of prostagladin E ₁ , phentolamine and verapamil.

The phentolamine blocks the alpha-adrenergic effect and reduces systemic vascular resistance and blood pressure within 2 minutes, the action lasts for 10-15 minutes, and increases the release of norepinephrine, resulting in heart rate and cardiac output. Increase.

Verapamil directly inhibits the eastern nodules, delays forward conduction through the atrioventricular nodules, reduces myocardial contractility, and is primarily used for the treatment of acute ventricular arrhythmias, and is also used for the treatment of angina, rather than nifedipine (NIFEDIPINE). It is not good, but it relaxes vascular smooth muscle and reduces blood pressure.

The erection-producing agent thus formed acts as follows. In this embodiment, a mixture of 20 μg of prostagladin E ₁ , 10 mg of phentolamine, and 40 mg of verapamil is used, and distilled water for injection is added as necessary. can do.

In the present embodiment, for convenience, it is divided into non- (B) group, C (C) group, D (D) group, and (E) group, and the non-group is a group whose penis is erection but does not maintain an erection state. The C-group is a group having an erection of penis, that is, a degree of stiffness of 50% or more, and the erectile group is hardly erection. It is divided into groups representing penis states between groups.

Of course, the prostagladin is a powder and phentolamine and verapamil are liquids, so the drugs are mixed with each other to form a liquid, and then the liquid is administered to the penis of the human body, and the dosage is age, weight, general state of health and administration time. And the route, the rate of excretion, the amount of concomitant medication, the severity of the particular disease being treated, and the like.

B group Serial Number Age (years) Dose (cc) Duration (minutes) One 27 0.2 60 2 30 0.24 60 3 40 0.16 80 4 41 0.18 60 5 43 0.1 60 6 44 0.25 60 7 45 0.06 60 8 47 0.2 60 9 48 0.14 80 10 50 0.16 60 11 51 0.12 80 12 52 0.25 60 13 53 0.2 60 14 54 0.06 60 15 55 0.18 60 16 58 0.3 60 17 61 0.17 50 18 63 0.26 60

As can be seen from the above chart, it is mainly distributed in the 40s and 50s, the dosage is not proportional to the age of the patient, the duration is also distributed in various ages, the various health conditions of patients It is important.

In other words, the erectile trigger according to the present invention can be seen that usually lasts more than 60 minutes in a fully erected state when administered 0.06cc ~ 0.26cc, as shown in the table above, in order to reduce the duration Smaller or injected

It is preferable to administer with distilled water.

C Group Serial Number Age (years) Dose (cc) Duration (minutes) One 30 0.24 80 2 37 0.27 50 3 41 0.24 50 4 45 0.35 60 5 47 0.34 40 6 50 0.35 60 7 50 0.22 50 8 51 0.3 60 9 55 0.35 60 10 58 0.35 60 11 60 0.3 40 12 63 0.3 50 13 64 0.3 40 14 65 0.34 30 15 71 0.34 40

As can be seen from the above diagram, it is mainly distributed in the 50s and 60s, the dosage is higher than the above-mentioned patients in the non- (B) group, it can be seen that the distribution of age is increased, the duration is also reduced. .

D Group Serial Number Age (years) Dose (cc) Duration (minutes) One 30 0.4 40 2 50 0.4 50 3 53 0.4 50 4 58 0.45 50 5 63 0.4 50

E Group Serial Number Age (years) Dose (cc) Duration (minutes) One 50 0.5 35 2 58 0.48 40 3 67 0.5 40

As can be seen from the two charts above, the distribution of ages belonging to the D and D groups is unknown, but the inputs form a distribution of 0.4 cc to 0.5 cc and persist in the erection state. It can be seen that the time required to decrease.

That is, even if the function of the erection is reduced by more than 50% to the state just before surgery, even if the dose of the drug is increased, the duration in the erection is reduced.

As described above, the erectile trigger of the present invention can be administered 0.04cc to 0.8cc, when the dosage is less than 0.04cc, the penis is easily erected, so that even if the erection is difficult or sustained, the duration is shortened. If the amount exceeds 0.8cc can not only maintain too much duration but also side effects due to overdose.

Thus, the erectile trigger of the present invention can be maintained to satisfy the erection duration while preventing further worsening, even if the erectile dysfunction is not treated.

As described above, the erection-producing agent according to the present invention has the advantage of reducing the pain that may occur after administration because it is directly administered to the penis by adding another drug, which is a safe drug, to prostagladin E ₁ .

In addition, the injectable drug of the present invention can be directly administered to the penis to effectively erect the penis, the drug itself is in a liquid state can be stored and used for a long time, there is another advantage that does not occur side effects such as fibrosis of the penis during long-term use .

Claims (2)

In a known erectile agent comprising a prostaglandin E ₁ which is a vasodilator, An erectile oil-producing agent obtained by mixing 0.05% to 1.50% of the prostagladin E ₁ , 20.00% to 40.00% of phentolamine, and 60.00% to 80.00% of verapamil in a weight ratio. The method of claim 1, An erection-producing agent comprising mixing 0% to 20% by weight of distilled water for injection.